Bevacizumab in recurrent glioma: Variable doses, volatile benefits by Sujith Kumar Mullapally, Pankaj Kumar Panda

Get full text

Protocol for bevacizumab purification using Ac-PHQGQHIGVSK-agarose by Gabriela R. Barredo, Silvana L. Giudicessi, María C. Martínez Ceron, Soledad L. Saavedra, Santiago Rodríguez, Lucas Filgueira Risso, Rosa Erra-Balsells, Gustavo Mahler, Fernando Albericio, Osvaldo Cascone, Silvia A. Camperi

“…Bevacizumab is a monoclonal antibody, produced in CHO cells, used for the treatment of many human cancers. …”
Get full text

Acute pancreatitis linked to bevacizumab: A case report by Arif Hakan Önder, Banu Öztürk, Ali Murat Tatlı, Erkan Kayıkçıoğlu

“…Introduction: The monoclonal anti-vascular endothelial growth factor antibody bevacizumab is increasingly being used in the treatment of malignant tumors. …”
Get full text

Treatment of polypoidal choroidal vasculopathy with intravitreal bevacizumab monotherapy by Colin S H Tan, Louis W Lim, Wei Kiong Ngo, Kai Xiong Cheong

Get full text

Bevacizumab in metastatic breast cancer: when may it be used? by Shari B. Goldfarb, Clifford Hudis, Maura N. Dickler

“…In this article we review the clinical trials testing the utility of bevacizumab for the treatment of metastatic disease.…”
Get full text

Gastrointestinal perforation associated with bevacizumab in metastatic colorectal cancer by Kunpeng Fang, Jie Wang, Jianyong Yuan, Chengjun Sui, Jiajun Zhi, Yong Xia, Minmin Sun

Subjects: Get full text

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab by Zhujun Liu, Zhujun Liu, Zhujun Liu, Zhujun Liu, Tingting Qin, Tingting Qin, Tingting Qin, Tingting Qin, Xiaohan Yuan, Xiaohan Yuan, Xiaohan Yuan, Xiaohan Yuan, Xiaohan Yuan, Jie Yang, Jie Yang, Jie Yang, Jie Yang, Jie Yang, Jie Yang, Jie Yang, Jie Yang, Wei Shi, Xiaoling Zhang, Xiaoling Zhang, Xiaoling Zhang, Xiaoling Zhang, Yanan Jia, Yanan Jia, Yanan Jia, Yanan Jia, Shaochuan Liu, Shaochuan Liu, Shaochuan Liu, Shaochuan Liu, Jing Wang, Jing Wang, Jing Wang, Jing Wang, Kai Li, Kai Li, Kai Li, Kai Li

Subjects: “…anlotinib abrogated bevacizumab resistance…”
Get full text

Bevacizumab in recurrent WHO grades II–III glioma by Soufyan Annakib, Soufyan Annakib, Valérie Rigau, Valérie Rigau, Amélie Darlix, Amélie Darlix, Catherine Gozé, Catherine Gozé, Catherine Gozé, Hugues Duffau, Hugues Duffau, Luc Bauchet, Luc Bauchet, Marta Jarlier, Michel Fabbro

Subjects: Get full text

Aflibercept monotherapy or bevacizumab first for diabetic macular edema by Avner Hostovsky, Iris Moroz, Gabriel Katz

Subjects: Get full text

In Vivo investigation of radiolabeled Bevacizumab in healthy rat tissues by Ilknur Demir, Fazilet Zumrut Biber Muftuler, Perihan Unak, Cigdem Acar

Subjects: Get full text

Bevacizumab for ocular neovascular diseases: a systematic review by Regis Bruni Andriolo, Maria Eduarda Puga, Rubens Belfort Júnior, Álvaro Nagib Atallah

“…Thus, the aim of this study was to evaluate the effectiveness and safety of bevacizumab for treating eye diseases involving increased local levels of VEGF, as the assumed pathophysiological mechanism. …”
Get full text

The Efficacy of Intravitreal Bevacizumab in Vitreous Hemorrhage of Diabetic Subjects by Cengiz Alagöz, Yusuf Yıldırım, Murat Kocamaz, Ökkeş Baz, Uğur Çiçek, Burcu Çelik, Halil İbrahim Demirkale, Ahmet Taylan Yazıcı, Muhittin Taşkapılı

Subjects: Get full text

Bevacizumab effect on viability of free groin flaps in rats by João Mamede, Manoel Odorico Moraes, Gabriel Pinheiro Furtado, Francisco Vagnaldo Fechine

Subjects: “…bevacizumab…”
Get full text

Clinical course of severe esophagitis following bevacizumab therapy by Jun-Ho Choi, Kwangwoo Nam

Get full text

Comment on “bevacizumab or laser for aggressive posterior retinopathy of prematurity” by Ramanuj Samanta

Get full text

Bevacizumab in advanced ovarian cancer: when, what for and why? by A S Tjulandina

Subjects: Get full text

Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma by Sedghipour MR, Mostafaei A, Taghavi Y

“…Bevacizumab was injected subconjunctivally at a dose of 0.2 mg. …”
Get full text

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab by Takayoshi Suga, Yuko Kimura, Kensuke Furuya, Hiroko Sato

“…Key Clinical Message Atezolizumab and bevacizumab combination therapy might be one of the treatment options for hepatocellular carcinoma concurrent with gastric adenocarcinoma.…”
Get full text

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports by Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang

Subjects: “…bevacizumab…”
Get full text

Circulating Tumor Cells and Bevacizumab Pharmacokinetics during Neoadjuvant Treatment Combining Chemotherapy and Bevacizumab for Early Breast Cancer: Ancillary Analysis of the AVASTEM Trial by Renaud Sabatier, Jean-Yves Pierga, Hervé Curé, Rakan Abulnaja, Eric Lambaudie, François-Clément Bidard, Jean-Marc Extra, Patrick Sfumato, Anthony Gonçalves

Subjects: Get full text